Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.

	Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
	Dai, Yang 1; Ji, Yichun 1; Shen, Yanyan 1; Su, Yi 1; Liu, Bo 1; Wang, Yueliang 1; Sun, Deqiao 1; Jiang, Yuchen 1; Zha, Chuantao 2; Xie, Zuoquan 1
刊名	CANCER IMMUNOLOGY RESEARCH
	2020-03-01
卷号	8 期号:3 页码:70-70
ISSN号	2326-6066
WOS研究方向	Oncology ; Immunology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000518188200112
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/281514]
专题	中国科学院上海药物研究所
作者单位	1.Shanghai Inst Mat Med, Shanghai, Peoples R China 2.Shanghai HaiHe Pharmaceut Co Ltd, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Dai, Yang,Ji, Yichun,Shen, Yanyan,et al. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.[J]. CANCER IMMUNOLOGY RESEARCH,2020,8(3):70-70.
APA	Dai, Yang.,Ji, Yichun.,Shen, Yanyan.,Su, Yi.,Liu, Bo.,...&Chen, Yi.(2020).Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models..CANCER IMMUNOLOGY RESEARCH,8(3),70-70.
MLA	Dai, Yang,et al."Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.".CANCER IMMUNOLOGY RESEARCH 8.3(2020):70-70.